These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25669213)

  • 21. Identifying persons with Lynch syndrome: why and how?
    Ladabaum U
    Dig Dis Sci; 2014 Dec; 59(12):2841-4. PubMed ID: 25344908
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost-effectiveness of genotyping in inherited arrhythmia syndromes: are we getting value for the money?
    Wilde AA; Pinto YM
    Circ Arrhythm Electrophysiol; 2009 Feb; 2(1):1-3. PubMed ID: 19808437
    [No Abstract]   [Full Text] [Related]  

  • 23. Estimated Cost-effectiveness of Genetic Testing in Siblings of Newborns With Cancer Susceptibility Gene Variants.
    O'Brien G; Christensen KD; Sullivan HK; Stout NK; Diller L; Yeh JM; Wu AC
    JAMA Netw Open; 2021 Oct; 4(10):e2129742. PubMed ID: 34661666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of colorectal cancer screening strategies.
    Tierney WM; Fendrick AM
    Gastroenterology; 1996 Jun; 110(6):2026-7. PubMed ID: 8964440
    [No Abstract]   [Full Text] [Related]  

  • 25. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms.
    Gagné G; Reinharz D; Laflamme N; Adams PC; Rousseau F
    Clin Genet; 2007 Jan; 71(1):46-58. PubMed ID: 17204047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis.
    Thomas C; Mandrik O; Saunders CL; Thompson D; Whyte S; Griffin S; Usher-Smith JA
    Cancer Prev Res (Phila); 2021 Aug; 14(8):811-822. PubMed ID: 34039685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Healthcare System-Funded Preventive Genomic Screening: Challenges for Australia and Other Single-Payer Systems.
    Lacaze P; Tiller J; Winship I
    Public Health Genomics; 2019; 22(3-4):140-144. PubMed ID: 31550728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Your Genes: Getting the Best Fit.
    Tempero M
    J Natl Compr Canc Netw; 2017 Sep; 15(9):1083. PubMed ID: 28874592
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland.
    de Gelder R; Bulliard JL; de Wolf C; Fracheboud J; Draisma G; Schopper D; de Koning HJ
    Eur J Cancer; 2009 Jan; 45(1):127-38. PubMed ID: 19038540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
    Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
    J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors.
    Smit AK; Newson AJ; Morton RL; Kimlin M; Keogh L; Law MH; Kirk J; Dobbinson S; Kanetsky PA; Fenton G; Allen M; Butow P; Dunlop K; Trevena L; Lo S; Savard J; Dawkins H; Wordsworth S; Jenkins M; Mann GJ; Cust AE
    Contemp Clin Trials; 2018 Jul; 70():106-116. PubMed ID: 29802966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The economics of genomic medicine: insights from the IOM Roundtable on Translating Genomic-Based Research for Health.
    Feero WG; Wicklund C; Veenstra DL
    JAMA; 2013 Mar; 309(12):1235-6. PubMed ID: 23532238
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost of exome sequencing in epileptic encephalopathy: is it 'worth it'?
    Forman EB; Gorman KM; Conroy J; Arthur N; Grant C; Ennis S; Allen NM; Lynch SA; King MD
    Arch Dis Child; 2018 Mar; 103(3):304. PubMed ID: 28939639
    [No Abstract]   [Full Text] [Related]  

  • 34. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness.
    Palmer EE; Schofield D; Shrestha R; Kandula T; Macintosh R; Lawson JA; Andrews I; Sampaio H; Johnson AM; Farrar MA; Cardamone M; Mowat D; Elakis G; Lo W; Zhu Y; Ying K; Morris P; Tao J; Dias KR; Buckley M; Dinger ME; Cowley MJ; Roscioli T; Kirk EP; Bye A; Sachdev RK
    Mol Genet Genomic Med; 2018 Mar; 6(2):186-199. PubMed ID: 29314763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.
    D'Andrea E; Marzuillo C; De Vito C; Di Marco M; Pitini E; Vacchio MR; Villari P
    Genet Med; 2016 Dec; 18(12):1171-1180. PubMed ID: 27906166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. msJAMA. Genomics in medicine and public health: role of cost-effectiveness analysis.
    Goldie SJ; Levin AR
    JAMA; 2001 Oct; 286(13):1637-8. PubMed ID: 11585493
    [No Abstract]   [Full Text] [Related]  

  • 37. Illumina claims $1,000 genome win.
    Sheridan C
    Nat Biotechnol; 2014 Feb; 32(2):115. PubMed ID: 24509738
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of the cost and effectiveness of diverse recruitment methods for a genetic screening study.
    Milo Rasouly H; Wynn J; Marasa M; Reingold R; Chatterjee D; Kapoor S; Piva S; Kil BH; Mu X; Alvarez M; Nestor J; Mehl K; Revah-Politi A; Lippa N; Ernst ME; Bier L; Espinal A; Haser B; Sinha A; Halim I; Fasel D; Cuneo N; Thompson JJ; Verbitsky M; Cohn EG; Goldman J; Marder K; Klitzman RL; Orjuela MA; So YS; Fedotov A; Crew KD; Kiryluk K; Appelbaum PS; Weng C; Siegel K; Gharavi AG; Chung WK
    Genet Med; 2019 Oct; 21(10):2371-2380. PubMed ID: 30930462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cost analysis of community screening for diabetes in the central Wisconsin Medicare population (results from the MetaStar pilot project in Wausau).
    Lee DS; Remington P; Madagame J; Blustein J
    WMJ; 2000 Jun; 99(3):39-43. PubMed ID: 10927980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
    Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.